The thing is that this base editing drug was developed to target the PCSK9 protein, which is important for controlling LDL-C levels through an LDL-C receptor.

Source: https://seekingalpha.com/article/4657286-verve-potential-to-advance-gene-based-editing-drugs-for-ascvd?source=feed_all_articles

The thing is that this base editing drug was developed to target the PCSK9 protein, which is important for controlling LDL-C levels through an LDL-C receptor.

Source: https://seekingalpha.com/article/4657286-verve-potential-to-advance-gene-based-editing-drugs-for-ascvd?source=feed_all_articles

The two patients treated with 0.45 mg/kg of VERVE-101 had a time-averaged LDL-C reduction of 39% and 48%.

Source: https://forextv.com/top-news/verve-therapeutics-announces-interim-data-for-verve-101-demonstrating-first-human-proof-of-concept-for-in-vivo-base-editing-with-dose-dependent-reductions-in-ldl-c-and-blood-pcsk9-protein-in-patients/